The role of new hepatitis B vaccines in South Africa
Vaccination is key to eliminating hepatitis B virus infection in South Africa (SA). Despite introducing immunisation in 1995, as part of the expanded programme of immunisation (EPI), hepatitis B virus infection remains endemic, and EPI vaccine coverage is incomplete. In addition to infants, non...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
South African Medical Association
2024-02-01
|
| Series: | South African Medical Journal |
| Subjects: | |
| Online Access: | https://samajournals.co.za/index.php/samj/article/view/1473 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860576633225216 |
|---|---|
| author | G U van Zyl T Maponga H Rabie J Taljaard |
| author_facet | G U van Zyl T Maponga H Rabie J Taljaard |
| author_sort | G U van Zyl |
| collection | DOAJ |
| description |
Vaccination is key to eliminating hepatitis B virus infection in South Africa (SA). Despite introducing immunisation in 1995, as part of the expanded programme of immunisation (EPI), hepatitis B virus infection remains endemic, and EPI vaccine coverage is incomplete. In addition to infants, non-immune adults at risk of infection through their occupation or with behavioural risk factors should receive vaccination. SA has many individuals with diabetes mellitus (a prevalence of almost 13%), obesity, HIV (8.45 million) or older age (5 million >60 years old), associated with a poorer vaccine response. Recently two new hepatitis B vaccines have been licensed: HEPLISAV-B includes an adjuvant that improves immunogenicity and has shown improved vaccine response in individuals with HIV, old age or diabetes mellitus. PreHevbrio, which includes three hepatitis B surface protein domains, instead of one, may also be more immunogenic, although clinical study data are still limited. These two novel vaccines have not yet been investigated in children and licensed in SA. Should HEPLISAV-B become available in SA, it may be particularly valuable to target high-risk groups in the country, such as people living with HIV, who show a poor response to the currently licensed vaccine.
|
| format | Article |
| id | doaj-art-730f9576279247a0b604c8da267dfa2a |
| institution | Kabale University |
| issn | 0256-9574 2078-5135 |
| language | English |
| publishDate | 2024-02-01 |
| publisher | South African Medical Association |
| record_format | Article |
| series | South African Medical Journal |
| spelling | doaj-art-730f9576279247a0b604c8da267dfa2a2025-02-10T12:26:27ZengSouth African Medical AssociationSouth African Medical Journal0256-95742078-51352024-02-01114210.7196/SAMJ.2024.v114i2.1473The role of new hepatitis B vaccines in South AfricaG U van Zyl0T Maponga1H Rabie2J Taljaard 3 Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; National Health Laboratory Service, Tygerberg Hospital, Cape Town, South AfricaDivision of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; National Health Laboratory Service, Tygerberg Hospital, Cape Town, South AfricaDepartment of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; Tygerberg Children’s Hospital, Cape Town, South AfricaDivision of Infectious Diseases, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; Tygerberg Academic Hospital, Cape Town, South Africa Vaccination is key to eliminating hepatitis B virus infection in South Africa (SA). Despite introducing immunisation in 1995, as part of the expanded programme of immunisation (EPI), hepatitis B virus infection remains endemic, and EPI vaccine coverage is incomplete. In addition to infants, non-immune adults at risk of infection through their occupation or with behavioural risk factors should receive vaccination. SA has many individuals with diabetes mellitus (a prevalence of almost 13%), obesity, HIV (8.45 million) or older age (5 million >60 years old), associated with a poorer vaccine response. Recently two new hepatitis B vaccines have been licensed: HEPLISAV-B includes an adjuvant that improves immunogenicity and has shown improved vaccine response in individuals with HIV, old age or diabetes mellitus. PreHevbrio, which includes three hepatitis B surface protein domains, instead of one, may also be more immunogenic, although clinical study data are still limited. These two novel vaccines have not yet been investigated in children and licensed in SA. Should HEPLISAV-B become available in SA, it may be particularly valuable to target high-risk groups in the country, such as people living with HIV, who show a poor response to the currently licensed vaccine. https://samajournals.co.za/index.php/samj/article/view/1473Hepatitis B virusVaccinesSouth AfricaImmunogenicityHIVDiabetes Mellitus |
| spellingShingle | G U van Zyl T Maponga H Rabie J Taljaard The role of new hepatitis B vaccines in South Africa South African Medical Journal Hepatitis B virus Vaccines South Africa Immunogenicity HIV Diabetes Mellitus |
| title | The role of new hepatitis B vaccines in South Africa |
| title_full | The role of new hepatitis B vaccines in South Africa |
| title_fullStr | The role of new hepatitis B vaccines in South Africa |
| title_full_unstemmed | The role of new hepatitis B vaccines in South Africa |
| title_short | The role of new hepatitis B vaccines in South Africa |
| title_sort | role of new hepatitis b vaccines in south africa |
| topic | Hepatitis B virus Vaccines South Africa Immunogenicity HIV Diabetes Mellitus |
| url | https://samajournals.co.za/index.php/samj/article/view/1473 |
| work_keys_str_mv | AT guvanzyl theroleofnewhepatitisbvaccinesinsouthafrica AT tmaponga theroleofnewhepatitisbvaccinesinsouthafrica AT hrabie theroleofnewhepatitisbvaccinesinsouthafrica AT jtaljaard theroleofnewhepatitisbvaccinesinsouthafrica AT guvanzyl roleofnewhepatitisbvaccinesinsouthafrica AT tmaponga roleofnewhepatitisbvaccinesinsouthafrica AT hrabie roleofnewhepatitisbvaccinesinsouthafrica AT jtaljaard roleofnewhepatitisbvaccinesinsouthafrica |